Bronchopulmonary dysplasia (BPD) is a chronic, severe, and often invalidating lung disease of preterm infants characterized by arrested alveolar and lung vascular growth (1) , leading to chronic need of oxygen supplementation until late in infancy and detrimental consequences on lung function and neurodevelopment in older children and adults.
Not all very or extremely preterm infants develop BPD. It is well known that some risk factors may increase the risk, but, to date, it is still unexplained why some infants develop BPD and others do not. The identification of an early marker to predict the risk is a major challenge.
Arrested vascular growth, one of the hallmarks of BPD, strongly contributes to the clinical outcome in preterm neonates. Experimental (2) and initial clinical data (3) suggest that circulating angiogenic cells may also be involved in the pathogenesis ofBPD.
Circulating double positive CD34+VEGFR-2+ and triple positive CD34+CDI33+VEGFR-2+ mononuclear cells are thought to be angiogenic cells of hematopoietic origin able to promote angiogenic processes (4) (5) (6) (7) . Indeed, in clinical observational studies, these cell populations have been demonstrated to correlate with a number of diseases with a major vascular component, including cardiovascular disease, systemic sclerosis, and idiopathic myelofibrosis (8) (9) (10) (11) . More specifically for BPD, mouse CD45-Sca-l+CDI33+VEGFR-2+ cells were found to be decreased, in an experimental model of BPD (2) . We speculated that the same three populations of cells could be implicated in lung vascular development, and that levels at birth could represent a biomarker of angiogenesis that may predict the risk of developing BPD in preterm infants.
We previously found no correlation between CD34+CD133+VEGFR-2+ cells and the development of BPD in a cohort of ninety-eight preterm infants (3). Here we present incremental data of a previously reported cohort, and definitely demonstrate the lack of association between the three above-mentioned cell populations and the risk of BPD in preterm infants.
MATERIALS AND METHODS

Study population and study design
Infants were included if they had gestational age < 32 weeks and/or birth weight < 1500 g, admitted within the first three hours of life to our single tertiary care neonatal intensive care unit at the Fondazione IRCCS Policlinico San Matteo di Pavia (Italy). Exclusion criteria were lack of parental informed consent, presence of known congenital/ chromosomal abnormalities, and first blood sample not collected within the first three hours of life. The years of recruitment were 2006-2009. Four infants died before 28 days of life, before diagnosis of BPD could be established, and before cystic PVL could be conclusively ruled out. Thirty-five infants (of whom 3 died before 28 days of life) were excluded from the study because of lack of parental informed consent (l infant), presence of known congenital! chromosomal abnormalities (l infant), and first blood sample not collected within the first three hours of life (33 infants).
The final cohort consisted of ninety-eight preterm infants included in a previous study (3), together with forty-four newly recruited infants. The percentages of triple positive CD34+CD133+VEGFR-2+ cells at birth had already been reported for the ninety-eight infants included in the previous study (3) . In these patients, flow cytometric data were retrospectively analyzed for other two cell populations, namely CD34+VEGFR-2+ and CD45-CD34+CDI33+VEGFR-2+ cells. The newly recruited neonates were studied for all the three cell populations at birth (within the first 3 hours of life), at 7 days, and at 28 days of life. A total of one hundred and forty-two preterm neonates were studied for the three cell populations at birth and 7 days of life; for a subset of infants (n=40), data of cell values at 28 days of life were also available.
The study protocol was approved by the Ethics Committee of the Institution. Written parental informed consent was obtained before blood collection according to the Declaration of Helsinki. Peripheral blood samples were never more abundant than 400 Ill, and were obtained during routine withdrawal for blood count.
The primary outcome was the association of baseline cell numbers with the development of BPD. BPD was defined as oxygen dependence for at least 28 postnatal days and graded at 36 weeks' postmenstrual age according to the fraction of inspired oxygen (FiO) and the requirement of respiratory support at this time: mild BPD was diagnosed if the infant was in room air, moderate BPD if the rro, was 0.22-0.29 and severe BPD if the rio, was 2: 0.30 or the infant was receiving respiratory support (12, 13) .
Other diseases of prematurity share common risk factors and common pathogenic mechanisms with BPD. Thus, to further understand the role of these cells in neonatal and fetal biology, we studied, as secondary lot . J . Immuoopathol. Pharmacol.
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11.8% Infant and maternal medical records were reviewed for pregnancy and delivery characteristics and for clinical data and outcomes. Cranial ultrasound imaging was routinely obtained within the first 24 hours of admission for all infants. Subsequently, serial cranial ultrasound examinations were carried out weekly until 31 weeks postmenstrual age, and at 36 and 40 weeks postmenstrual age for all infants, or when clinically indicated; infants with gestational age < 27 weeks had an additional cranial ultrasound at 48-72 hours. The same protocol had been used for the ninety-eight infants included in the previous study. Cystic periventricular leukomalacia (PYL) was defined as echodensity in the white matter dorsal and lateral to the lateral ventricles with evolution into echolucent cysts. Intraventricular haemorrhage (IYH) was graded according to Papile et al. (16) . PDA was diagnosed by echocardiogram. The clinical risk index for babies (CRIB) score, for the prediction of neonatal mortality and morbidity, was calculated as previously described ( 17) . The diagnosis of early-onset sepsis (within the first 72 hours of life) and late-onset sepsis (after the first 72 hours of life), was based on signs of infection accompanied by abnormal laboratory studies and/or positive cultures.
Flow cytometry
The percentages of circulating cell populations were assessed by flow cytometry (Fig. I for one representative patient). The staining procedure was performed in all the neonates on 50 III of EDTA-whole blood samples. The isotype control was performed staining the blood cells with 5 III of FITC-lgG I, biotin-conjugated-IgG I revealed with PerCp-streptavidin, PE-IgG I, and APC-IgG I. An additional blood sample was stained with FITC-anti-CD34 antibody, biotin-conjugated-IgG I revealed with PerCp-streptavidin, PE-IgG I, and APC-IgG I; this tube allowed to electronically gate the CD34+ cells to be analysed in a PE-IgG I versus PerCP-IgG I dot plot. The percentage of CD34+CDl33+VEGFR-2+CD45-cells was then evaluated by staining the blood sample with 10 III The percentage of CD34+VEGFR-2+ cells was calculated on electronically gated mononuclear cells. Differently, the evaluation ofCD34+CD I33+VEGFR-2+, and CD45-CD34+CDI33+VEGFR-2+ cells was calculated as percentage of electronically gated CD34+ cells as shown for one representative patient (Fig. I) .
The cytofluorimeter is validated according to the UKNECAS external quality control for leukocyte immunophenotyping. The percentage of positive cells was obtained by subtracting the value of the appropriate isotype controls.
Statistical analysis
The frequencies of parametric and non-parametric continuous variables are reported as mean ± standard deviation (SD) and median and range, respectively. Categorical variables are described by count and relative frequency (%). Comparison between groups ofcontinuous parametric and non-parametric variables was carried out using the Student's r-test for independent samples and the non-parametric Mann-Whitney U-test, respectively. Categorical variables were compared between groups using the Fisher's exact test. The Spearman's correlation coefficient was used for univariate correlations.
Analysis of correlation of cell percentages with clinical outcomes (diseases ofprematurity) was performed excluding infants who died before 28 days of life (that is, in a population of one-hundred and thirty-eight infants); correlation of cell percentages at birth with perinatal factors, CRIB score, white blood cell counts at birth, erythroblasts at birth, and mortality, was performed on the entire population of one-hundred and forty-two infants. A P value < 0.05 was considered statistically significant for all analyses. All analyses were performed using MedCalc® v9.5.1.0 software.
RESULTS
Lack of correlation between cell populations and clinical outcomes
Maternal, perinatal, and neonatal characteristics of the study infants are reported in Table I . We first analyzed whether circulating levels of CD34+VEGFR-2+, CD34+CD I33+VEGFR-2+, and CD45-CD34+CDI 33+VEGFR-2+ cells at birth correlate with the subsequent development of BPD or other diseases of prematurity.
At univariate analysis, CD34+VEGFR-2+, CD34+CDI33+VEGFR-2+, and CD45-CD34+CDI33+VEGFR-2+ cell counts were comparable in infants with and without BPD (P=O.91, P=O.71, and P=O.71, respectively; Fig. 2 ).
When infants with no BPD were analyzed together with infants with mild BPD and compared to infants with moderate-to-severe BPD, we found no significant differences in cell percentages between the two groups (P=O.56, P=0.45, and P=O.77; Fig. 2) .
Similarly, no correlation was found between cell percentages and any disease of prematurity, including cystic PVL, IVH, ROP, NEC, early-or late-onset sepsis, or PDA (Data not shown).
Cell populations and maternal/perinatalfactors
We then asked whether a correlation existed between cell percentages at birth and the presence of perinatal factors, some of which are known to influence the development of BPD. In our study, circulating levels of CD34+VEGFR-2+, CD34+CD133+VEGFR-2+, and CD45-CD34+CD133+VEGFR-2+ cells at birth did not correlate with the presence ofmaternal hypertension, chorioamnionitis, gestational age and birth weight, gender, multiple pregnancy, cesarean section, and small for gestational age; only a slight increase in triple-positive CD34+CD133+VEGFR-2+ CD34+CDI33+VEGFR-2+ cells and white blood cell counts at birth, and only a small correlation was found between CD34+VEGFR-2+ and white blood cell counts at birth (Data not shown).
Cell populations and severity of the clinical conditions
In order to determine whether the three cell populations may represent a marker of severity of the clinical conditions of pretenn infants, we studied the cell percentages for correlation with the CRIB score, erythroblast counts at birth (a marker of illness severity), and mortality risk. However, we did not detect any correlation between these variables and cell percentages (Data not shown).
Cell populations after the first week oflife
When we analyzed the counts of the three cell populations at 7 days and, in a subset of infants (n=40, 14 with BPD and 26 without BPD), at 28 days of life, we found no association with BPD or with the risk of any other disease of prematurity (data not shown). Importantly, cell percentages at 28 days of life did not correlate with Fi02 values at 28 days (r=0.08, P=0.59; r=0.03, P=0.66; and r=0.138, P=0.43, for the three cells populations) or at 36 weeks postmenstrual age (r= -0.17, P=0.24; r= -0.11, P=0.44; and r=0.18, P=0.28), and were not different in infants exposed to oxygen for more than 15 days compared to infants exposed to oxygen for less than 15 days (P=0.63, P=0.50, and P=0.37).
DISCUSSION
We studied, by flow cytometry, the percentages at birth, at 7 days and at 28 days of life, of three circulating cell populations of hematopoietic progenitors with angiogenic properties in pretenn infants, for correlation with BPD, a pulmonary disease of the premature infant characterized by impaired lung vascular development; in our study we did not find any correlation between the enumerated cell populations and BPD or any other disease associated with premature birth.
We chose to study CD34+VEGFR-2+ and CD34+CD133+VEGFR-2+ cells, because both cells had been previously associated with diseases with vascular dysfunction (8-10), and had beeñ Fig. 2. CD34+VEGFR-2+, CD34+CDJ33+VEGFR-2+ , and CD45-CD34+CDJ33+VEGFR-2+ cells in infants without BPD and in infants with mild or moderate-severe BPD.
cells but not CD34+VEGFR-2+ and CD45-CD34+CDI33+VEGFR-2+ cells was observed in infants who had received antenatal steroids. Furthermore, we found no correlation between CD34+CD133+VEGFR-2+ and CD45- proposed as biomarkers of cardiovascular risk (18) . In addition, the mouse counterpart of CD45-CD34+CD133+VEGFR-2+ cells was demonstrated to be reduced in circulating blood of neonatal mice after exposure to oxygen (2) . In an attempt to identify early predictors of BPD, we correlated cell percentages at birth with the subsequent risk of developing BPD. Indeed, BPD is characterized by dysmorphic vascular changes (19, 20) , and circulating angiogenic cells may be implicated in pulmonary angiogenesis. However, CD34+VEGFR-2+, CD34+CD133+VEGFR-2+, and CD45-CD34+CD133+VEGFR-2+ cells at birth identified with our flow cytometry protocol failed to predict the risk of BPD. This finding is in agreement with our previous report on a lower number of patients (3) and with a recent report (21) . Other polychromatic flow cytometry protocols (PFC) may be more useful for the identification and enumeration of specific cell populations directly involved in lung vascular development (22, 23) . Interestingly, a recent clinical study by Baker et al. conducted using this novel PFC protocol showed a significantly lower ratio of angiogenic circulating progenitors to non-angiogenic circulating progenitors in cord blood samples of preterm infants who subsequently developed moderate or severe BPD (24) .
Furthermore, the three cell populations do not seem to be implicated in the pathogenesis of any outcome or neonatal disease of prematurity and are not influenced by perinatal factors.
In conclusion, CD34+VEGFR-2+, CD34+CD133+VEGFR-2+, and CD45-CD34+CDI33+VEGFR-2+ cells at birth failed to predict the subsequent development of BPD or any other disease of prematurity, and we discourage further studies. Research is needed to find other markers or predictors able to early identify infants at risk ofBPD. Our study also underlines the importance of human studies (as opposed to animal studies) to understand the pathogenesis of BPD and to improve its clinical management.
